Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany

13 Jun 2022

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

13 Jun 2022

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM

10 Jun 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control

9 Jun 2022

ASCO 2022: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

6 Jun 2022

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Dr Julie Gralow- Chief Medical Officer, ASCO

$Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )$

5 Jun 2022

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Dr Martin McCabe- University of Manchester, Manchester, England

$Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )$

5 Jun 2022

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$